Published Date: 02 Mar 2023
A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.
Read Full News1.
AI catches one-third of interval breast cancers missed at screening
2.
Novel Psychedelic Promising on Resistant Depression
3.
Colon cancer and exercise: Can physical activity reprogram genes?
4.
Research suggests peer support may lower depression, stress among cancer patients in low-resource settings
5.
FDA Expands Use of T-DXd in Early HER2+ Breast Cancer
1.
Understanding Colon Cancer: Symptoms, Causes, and Treatment Options
2.
The Converging Frontiers of Radiation Oncology and Systemic Therapies by 2025
3.
Landmark Medical Oncology Trials Redefining Early Breast Cancer Management
4.
Cancer Staging: Updates, Clinical Insights, and Educational Resources for Medical Professionals
5.
Integrated Frameworks in Hematology in Clinical Decision-Making
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
International Lung Cancer Congress®
1.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
2.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias
3.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II
4.
Navigating the Complexities of Ph Negative ALL - Part XI
5.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation